Hosp. Universitario San Joan de Reus, (Spain)
Reus, Tarragona, 43201, Spain
NCT Number: NCT00502047
The hypothesis of this study is that soluble fibre may contribute to a reduction of the low density lipoprotein cholesterol (LDL-c), and the combined effect with a statin may achieve an optimisation of the cholesterol-lowering effects in adults with several cardiovascular risk factors.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Phase 2 / Phase 3
Reus, Tarragona, 43201, Spain
It has been demonstrated that high concentrations of cholesterol and low density lipoprotein cholesterol (LDL, high risk cholesterol) are the major risk factors for heart disease, myocardial infarction and angina pectoris. Moreover, these conditions represent the major cause of death in the Western world.
Of the measures established to reduce blood cholesterol levels, the introduction of consumption of dietary fibre is a novelty. The term dietary fibre defines a variety of substances that are found in plants and are resistant to digestion by human gastrointestinal enzymes.
The studies performed up until now to determine the effects of fibre on blood lipids have demonstrated that consumption of soluble fibre can reduce cholesterol.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 16 weeks
Time frame: 16 weeks
Time frame: 16 weeks
Time frame: 16 weeks
Rottapharm Spain
Industry
Multicentre, Comparative, Double-Blind, Two-Arm Parallel Clinical Trial of the Effects of Treatment With Plantago Ovata Husk on the Lipid Profile of Patients With Hypercholesterolemia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02857543
Body Weight, Cardiovascular Disease
Cleveland, Ohio, United States
View Trial DetailsNCT01817491
Body Weight, Cardiovascular Disease
Cleveland, Ohio, United States
View Trial DetailsNCT02391701
Adiposity, Body Weight
Santiago de Compostela, Spain
View Trial DetailsNCT02341664
Angina, Angina Pectoris
Little Rock, Arkansas, United States
View Trial Details